Heron stock: buy or sell?
May 21st, 2019
Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single subcutaneous injection.
Should I buy Heron stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Heron stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Heron Therapeutics stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 3 ratings published for HRTX stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-1-16||Needham & Company LLC||Buy||Buy|
Heron stock analysis
Heron Therapeutics shares rose 2.86% to $18.32 today.
Heron Therapeutics shares rose 2.86% to $18.32 today. Since price and SMA100d lines crossed down on Apr 9th, HRTX fell $-7.82 per share (-29.92%).
Heron Therapeutics shares grew 1.44% this week, ending at $18.32. Late April HRTX collapsed a spooky -42.18% in just one week. With this, it's been 3 climbing weeks in a row, soaring a 5.46%. Early May HRTX boosted an impressive 5.56% in just one week.
Since price and 20-weeks moving average lines crossed down early April, HRTX fell $-7.77 per share (-29.78%).
Heron stock price history
Heron IPO was on August 27th, 1987 at $580.00 per share1. Since then, HRTX stock sliced a -96.80%, with a yearly average of -3.10%.
1: Adjusted price after possible price splits or reverse-splits.
Heron stock historical price chart
HRTX stock reached 52-week highs on June at $42.90, and all-time highs 1992-01-13 with a price of 1290.
Heron stock price target is $64.00Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. Currently, only 1 price prediction for Heron stock was published in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-1-16||Needham & Company LLC||Reiterates||$66.00||$64.00||-3%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Heron presented its financial report, posting a super good climb for the Earnings per Share (EPS). Analyst expected $-0.46 per share, but Heron posted $-0.63.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual turnover report draw an amazing gain of 151.81% to $77.47 M dollars. When comparing 2018 vs 2017, likewise, profit margin (that is, the net income divided by revenues) climbed a 411.03% to -230.84%.
|2016||$1.28 M||-||$-173.14 M-13537.4%||-|
|2017||$31 M||2,305.55%||$-197.48 M-641.9%||14.06%|
|2018||$77 M||151.81%||$-178.84 M-230.8%||-9.44%|
Quarterly financial resultsHeron Therapeutics posted $28.84 million in revenues for 2018-Q4, a 45.78% improvement compared to previous quarter. Reported quarter earnings marked $-49.56 million with a profit margin of -171.82%. Profit margin rocketed a 21.99% compared to previous quarter when profit margin was -193.80%. When comparing sales to same quarter last year, Heron sales marked an exceptional increase and skyrocketed a 186.92%. Looking back to recent quarterly results, Heron posted 7 negative quarters in a row.
|2017-Q1||$4 M||-||$-50.33 M-1386.5%||-|
|2017-Q2||$9 M||134.44%||$-42.80 M-502.9%||-14.96%|
|2017-Q3||$9 M||0.73%||$-41.87 M-488.4%||-2.18%|
|2017-Q4||$10 M||17.28%||$-62.49 M-621.6%||49.26%|
|2018-Q1||$12 M||15.06%||$-52.27 M-451.8%||-16.36%|
|2018-Q2||$17 M||49.36%||$-38.67 M-223.8%||-26.01%|
|2018-Q3||$20 M||14.52%||$-38.35 M-193.8%||-0.84%|
|2018-Q4||$29 M||45.78%||$-49.56 M-171.8%||29.24%|
Heron ownershipWhen you are planning to buy a company, it's always worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Heron Therapeutics, 0.13% of all outstanding shares are owned by its staff.
Bearish positions for HRTX stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$1.5 B||$406.4 M||$3.9 B||$118.5 M||$71.5 M|
|Total shares||79.2 M||138.7 M||156.9 M||162.4 M||74.4 M|
|Float shares||66.0 M||124.7 M||155.1 M||155.9 M||27.1 M|
|- Institutional holdings (%)||117.6%||78.6%||99.2%||46.1%||24.4%|
|- Insider holdings (%)||0.1%||0.1%||0.9%||4.0%||63.7%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Tuesday, May 21st, 2019|
|Day range||$17.40 - $18.32|
|Average true range||$0.85|
|50d mov avg||$22.32|
|100d mov avg||$24.48|
|200d mov avg||$27.88|
Heron performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For Heron, the comparison is made against Achillion Pharmaceuticals, Alkermes, DURECT, Insys Therapeutics, Ligand Pharmaceuticals, Nektar, Pacira Pharmaceuticals and Surmodics.